
    
      Patients â‰¥18 years old who have large volume of pleural effusion, required evacuation, and
      received systemic therapy with a checkpoint inhibitor (monotherapy or combination with
      another checkpoint inhibitor) for metastatic cancers (renal cell carcinoma (RCC) and
      non-small cell lung cancer (NSCLC) will be eligible. Drainage followed by nivolumab (40 mg,
      single intrapleural instillation) will be performed.
    
  